NASDAQ 
Incyte trades at $67 per share and has moved almost in lockstep with the market over the last six months. The stock has lost 6.6% while the S&P 500 is...
Incyte INCY announced that the FDA has approved its new drug, Zynyz (retifanlimab-dlwr), a PD-1...
Graham Capital Management L.P. acquired a new position in shares of Incyte Co. (NASDAQ:INCY – Free Report) in the fourth quarter, Holdings Channel.com reports. The firm acquired 3,673 shares ...
After the top trio, Janus Henderson Group (NYSE:JHG) saw 29.8% of its float snapped up, followed by Wendy's (NASDAQ:WEN) at 22.8%, Incyte (NASDAQ:INCY)...
Incyte (NASDAQ:INCY), a $12.1 billion biopharmaceutical company with strong financial health according to InvestingPro metrics, has received U.S. Food and Drug Administration (FDA) approval ...
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the...
Regeneron agreed to take measures to ensure the ethical use and security of 23andMe's customer data....
Some of the biggest gainers on Tuesday have the weakest relative-strength profiles, including DLTR, DG, REGN (highlighted in the next column), HUM, MTD, CE, INCY, HOG, PFE, ELV, UA, and WBD, ...
